Background: Cancer is defined as group of diseases with uncontrolled cell growth.rnInflammation is linked with cancer and stated as one of the hallmarks of cancer. hs-CRP, anrnacute-phase plasma protein that increases during systemic inflammation, is one of the mostrnfrequently used inflammatory biomarker. Similarly, serum ferritin, which is commonly used andrnconvenient biomarker to assess iron level in the body is recently used as an important marker ofrninflammation. However, both hsCRP and serum ferritin level was not commonly used for earlyrnscreening, prognosis or diagnosis of cancer. rnObjective: The aim of this study was to assess serum ferritin and hs-CRP level in breast,rncervical and colorectal cancer before any treatment. rnMethods: Hospital based cross-sectional study was used as an appropriate study design. A totalrnof 120 breast, cervical and colorectal cancer patients (40 in each cancer type), who did not takernany type of treatment were included in this study. Biochemical tests of serum ferritin and hsCRPrnlevel were determined using COBAS c 501 and COBAS e 411 rack systems, respectively.rnComparison of medians of serum ferritin and hsCRP among cancer types and among cancerrnstage was assessed using Kruskal- Wallis H tests. P-values less than 0.05 were considered to bernstatistically significant. rnResults: Increased level of hsCRP was observed on breast cancer (22.5 %), cervical cancerrn(50%), and CRC (37.3%) patients. Similarly, elevated serum ferritin level was observed onrn12.5% breast, 30% cervical and 42.5% of colorectal cancer patients. Based on the stage ofrncancer, higher median (interquartile) value of hsCRP and serum ferritin was noticed on stage IVrnand II cancer patients respectively. Significantly higher median value of hsCRP was observed onrncervical cancer patients (p< 0.005). But, insignificantly higher level of serum ferritin and higherrnlevel of serum hsCRP was seen on stage II (p=0.259) and stage IV (p=0.702) cancer patients,rnrespectively. rnConclusion: The current study proved that there was increment of serum ferritin and hsCRP inrnthe three cancer cases. As a result, serum ferritin and hsCRP can be used as potential diagnosticrnbiomarkers in breast, cervical and colorectal cancer.